Bright Minds Biosciences Inc.
DRUG
株式のランク
#12683
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics... Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
株価
$52.67
時価総額
$519.58M
変化（1日）
4.43%
変化（1年）
-13.15%
国
US
取引 Bright Minds Biosciences Inc. (DRUG)
カテゴリー
Healthcare
Bright Minds Biosciences Inc.（DRUG）の株価履歴
終値の最高値: $53.83 （2026-10-01）
終値の最安値: $33.56 （2021-02-01）
終値の最安値: $33.56 （2021-02-01）
Bright Minds Biosciences Inc. の株価履歴（2021 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | -8.79% |
| 2025 | 105.52% |
| 2024 | 2,581.73% |
| 2023 | -68.72% |
| 2022 | -73.66% |
| 2021 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
